Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772825 | 0.98 | MAP1LC3B (0.51) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL23772670 | 0.98 | MAP1LC3B (0.51) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL23772439 | 0.98 | MAP1LC3B (0.51) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL25756460 | 0.92 | MAP1LC3B (0.52) | CRBNMAP1LC3BBRD4IKZF3 | |
| SCHEMBL25031848 | 0.92 | MAP1LC3B (0.52) | CRBNMAP1LC3BBRD4IKZF3 | |
| SCHEMBL25756266 | 0.92 | MAP1LC3B (0.49) | CRBNMAP1LC3BBRD4IKZF3 | |
| SCHEMBL24777871 | 0.89 | CRBN (0.57) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL13621972 | 0.88 | CRBN (0.58) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL30250216 | 0.88 | CRBN (0.58) | CRBNMAP1LC3BBRD4TNFIL1B | |
| SCHEMBL25376586 | 0.87 | MAP1LC3B (0.59) | CRBNMAP1LC3BBRD4TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | Aurigene Oncology Technologies Limited (IN) | 2024-08-15 | — | — | US | disclosed |
| US-11530195-B1 | Protacs targeting coronavirus 3CL protease and preparation method and application thereof | Shaanxi Panlong Pharmaceutical Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| CN-112771038-A | Pyridazine derivatives as SMARCA2/4 degradants | 奥里吉恩发现科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3784665-A1 | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS | Aurigene Discovery Technologies Limited (IN) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885MAP1LC3B 3015/4885BRD4 75/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 384/4885MAP1LC3B 2944/4885BRD4 75/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885MAP1LC3B 3015/4885BRD4 75/4885 |
| US-11530195-B1 | Protacs targeting coronavirus 3CL protease and preparation method and application thereof | TMPRSS2, TMPRSS11D, CTRL | CRBN 118/4885MAP1LC3B 913/4885BRD4 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.